Aspirin News and Research RSS Feed - Aspirin News and Research

Aspirin also known as acetylsalicylic acid is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet, or "anti-clotting", effect and is used in long-term, low doses to prevent heart attacks, strokes and blood clot formation in people at high risk for developing blood clots. It has also been established that low doses of aspirin may be given immediately after a heart attack to reduce the risk of another heart attack or of the death of cardiac tissue.
Current menopausal hormone therapy users at increased risk of experiencing GI bleeding

Current menopausal hormone therapy users at increased risk of experiencing GI bleeding

Current users of menopausal hormone therapy (MHT) are more than twice as likely than non-users to develop lower gastrointestinal bleeding and ischemic colitis, especially if they use the therapy for longer durations, according to a study at Digestive Disease Week 2015. [More]
Regular use of aspirin may slow the progression of early emphysema, new research shows

Regular use of aspirin may slow the progression of early emphysema, new research shows

Regular use of aspirin may help slow the progression of early emphysema, according to new research presented at the 2015 American Thoracic Society International Conference. [More]
Major breakthrough provides new insights into how tinnitus develops

Major breakthrough provides new insights into how tinnitus develops

Tinnitus is the most common service-related disability for veterans returning from Iraq and Afghanistan. Often described as a ringing in the ears, more than 1.5 million former service members, one out of every two combat veterans, report having this sometimes debilitating condition, resulting in more than $2 billion dollars in annual disability payments by the U.S. Department of Veterans Affairs. [More]
Survey: 52% of acute coronary syndrome patients don't take their prescribed OAP therapy

Survey: 52% of acute coronary syndrome patients don't take their prescribed OAP therapy

People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent are prescribed an oral antiplatelet (OAP) therapy and aspirin to help prevent a heart attack, a blood clot in their heart stent (stent thrombosis), or even death. [More]
Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. [More]
Aspirin use continues to surge among older adults in US

Aspirin use continues to surge among older adults in US

A national survey suggests that slightly more than half of the older adults in the United States are now taking a daily dose of aspirin, even though its use is not recommended by the Food and Drug Administration for most people who have not yet had a heart attack or stroke. [More]
Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII. [More]
Use of balloon-expandable stent compared with medical therapy increases stroke risk

Use of balloon-expandable stent compared with medical therapy increases stroke risk

Among patients with symptomatic intracranial arterial stenosis (narrowing of an artery inside the brain), the use of a balloon-expandable stent compared with medical therapy (clopidogrel and aspirin) resulted in an increased of stroke or transient ischemic attack (TIA), according to a study in the March 24/31 issue of JAMA. [More]
UM experts warn of serious risks associated with common IV devices

UM experts warn of serious risks associated with common IV devices

Every day, patients around the country get IV devices placed in their arms, to make it easier to receive medicines or have blood drawn over the course of days or weeks. But these PICC lines, as they're called, also raise the risk of potentially dangerous blood clots. [More]
How our DNA may prevent bowel cancer

How our DNA may prevent bowel cancer

The link between taking aspirin, and similar medications called non-steroidal anti-inflammatory drugs (or NSAIDS), and bowel (colorectal) cancer prevention is well established. [More]
New anti-clotting therapy no better than established anticoagulants

New anti-clotting therapy no better than established anticoagulants

A novel therapy that would allow doctors to turn the body's blood-clotting ability off and on in a more controlled way was about as effective as established anticoagulants in patients undergoing angioplasty but was associated with higher rates of moderate to severe bleeding, according to an analysis of data from a terminated Phase III trial presented at the American College of Cardiology's 64th Annual Scientific Session. [More]
Genetic markers may help decide who benefits from aspirin, NSAIDs in lowering risk of colorectal cancer

Genetic markers may help decide who benefits from aspirin, NSAIDs in lowering risk of colorectal cancer

An Indiana University cancer researcher and her colleagues have identified genetic markers that may help determine who benefits from regular use of aspirin and other nonsteroidal anti-inflammatory drugs for lowering one's risk of developing colorectal cancer. [More]
Egalet announces net revenues of $1.9 million for 2014

Egalet announces net revenues of $1.9 million for 2014

Egalet Corporation today reported financial results for the year ended December 31, 2014. [More]
Naproxen and omeprazole combination effective in preventing bladder cancer

Naproxen and omeprazole combination effective in preventing bladder cancer

The anti-inflammatory class of drugs NSAIDs have shown great promise in preventing cancers including colon, esophagus and skin. However, they can increase the risks of heart attacks, ulcers and rare but potentially life-threatening bleeds. [More]
People who exhibit resistance to aspirin may be at risk of more severe strokes

People who exhibit resistance to aspirin may be at risk of more severe strokes

People who exhibit a resistance to aspirin may be more likely to have more severe strokes than people who still respond to the drug, according to a study released today that will be presented at the American Academy of Neurology's 67th Annual Meeting in Washington, DC, April 18 to 25, 2015. [More]
Researchers find key protein critical to the success of common anti-platelet drug Plavix

Researchers find key protein critical to the success of common anti-platelet drug Plavix

Researchers at the UNC School of Medicine have found that the blood platelet protein Rasa3 is critical to the success of the common anti-platelet drug Plavix, which breaks up blood clots during heart attacks and other arterial diseases. [More]
Trinity scientists reveal new marvel molecule that can block key process in inflammatory diseases

Trinity scientists reveal new marvel molecule that can block key process in inflammatory diseases

Scientists at Trinity College Dublin have uncovered a marvel molecule that blocks a key driver of inflammatory diseases. The finding could meet a major unmet clinical need by inspiring new non-invasive treatments for arthritis, multiple sclerosis and Muckle-Wells syndrome, among a myriad of other inflammatory diseases. [More]
Study: Most risk calculators used by clinicians overestimate risk of heart attack

Study: Most risk calculators used by clinicians overestimate risk of heart attack

Most "risk calculators" used by clinicians to gauge a patient's chances of suffering a heart attack and guide treatment decisions appear to significantly overestimate the likelihood of a heart attack, according to results of a study by investigators at Johns Hopkins and other institutions. [More]
Widely used clinical calculators overrate heart attack risk

Widely used clinical calculators overrate heart attack risk

Most "risk calculators" used by clinicians to gauge a patient's chances of suffering a heart attack and guide treatment decisions appear to significantly overestimate the likelihood of a heart attack, according to results of a study by investigators at Johns Hopkins and other institutions. [More]
Cumberland initiates clinical development of Boxaban (ifetroban) oral capsule for AERD treatment

Cumberland initiates clinical development of Boxaban (ifetroban) oral capsule for AERD treatment

Cumberland Pharmaceuticals Inc. today announced an expansion of its pipeline with a new Phase II development program. The Company has initiated the clinical development of Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease (AERD). [More]
Advertisement
Advertisement